BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen

Alex M. Ayoub, Laura M.L. Hawk, Ryan J. Herzig, Jiewei Jiang, Andrea J. Wisniewski, Clifford T. Gee, Peiliang Zhao, Jin Yi Zhu, Norbert Berndt, Nana K. Offei-Addo, Thomas G. Scott, Jun Qi, James E. Bradner, Timothy R. Ward, Ernst Schönbrunn, Gunda I. Georg, William C.K. Pomerantz

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Chemical inhibition of epigenetic regulatory proteins BrdT and Brd4 is emerging as a promising therapeutic strategy in contraception, cancer, and heart disease. We report an easily synthesized dihydropyridopyrimidine pan-BET inhibitor scaffold, which was uncovered via a virtual screen followed by testing in a fluorescence anisotropy assay. Dihydropyridopyimidine 3 was subjected to further characterization and is highly selective for the BET family of bromodomains. Structure-Activity relationship data and ligand deconstruction highlight the importance of the substitution of the uracil moiety for potency and selectivity. Compound 3 was also cocrystallized with Brd4 for determining the ligand binding pose and rationalizing subsequent structure-Activity data. An additional series of dihydropyridopyrimidines was synthesized to exploit the proximity of a channel near the ZA loop of Brd4, leading to compounds with submicromolar affinity and cellular target engagement. Given these findings, novel and easily synthesized inhibitors are being introduced to the growing field of bromodomain inhibitor development.

Original languageEnglish (US)
Pages (from-to)4805-4817
Number of pages13
JournalJournal of Medicinal Chemistry
Volume60
Issue number12
DOIs
StatePublished - Jun 22 2017

Fingerprint

Ligands
Fluorescence Polarization
Uracil
Structure-Activity Relationship
Contraception
Epigenomics
Heart Diseases
Neoplasms
Proteins
Therapeutics

Cite this

BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. / Ayoub, Alex M.; Hawk, Laura M.L.; Herzig, Ryan J.; Jiang, Jiewei; Wisniewski, Andrea J.; Gee, Clifford T.; Zhao, Peiliang; Zhu, Jin Yi; Berndt, Norbert; Offei-Addo, Nana K.; Scott, Thomas G.; Qi, Jun; Bradner, James E.; Ward, Timothy R.; Schönbrunn, Ernst; Georg, Gunda I.; Pomerantz, William C.K.

In: Journal of Medicinal Chemistry, Vol. 60, No. 12, 22.06.2017, p. 4805-4817.

Research output: Contribution to journalArticle

Ayoub, AM, Hawk, LML, Herzig, RJ, Jiang, J, Wisniewski, AJ, Gee, CT, Zhao, P, Zhu, JY, Berndt, N, Offei-Addo, NK, Scott, TG, Qi, J, Bradner, JE, Ward, TR, Schönbrunn, E, Georg, GI & Pomerantz, WCK 2017, 'BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen', Journal of Medicinal Chemistry, vol. 60, no. 12, pp. 4805-4817. https://doi.org/10.1021/acs.jmedchem.6b01336
Ayoub, Alex M. ; Hawk, Laura M.L. ; Herzig, Ryan J. ; Jiang, Jiewei ; Wisniewski, Andrea J. ; Gee, Clifford T. ; Zhao, Peiliang ; Zhu, Jin Yi ; Berndt, Norbert ; Offei-Addo, Nana K. ; Scott, Thomas G. ; Qi, Jun ; Bradner, James E. ; Ward, Timothy R. ; Schönbrunn, Ernst ; Georg, Gunda I. ; Pomerantz, William C.K. / BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 12. pp. 4805-4817.
@article{1ba7ea4c81114c3bb8f96cf6bc2f276a,
title = "BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen",
abstract = "Chemical inhibition of epigenetic regulatory proteins BrdT and Brd4 is emerging as a promising therapeutic strategy in contraception, cancer, and heart disease. We report an easily synthesized dihydropyridopyrimidine pan-BET inhibitor scaffold, which was uncovered via a virtual screen followed by testing in a fluorescence anisotropy assay. Dihydropyridopyimidine 3 was subjected to further characterization and is highly selective for the BET family of bromodomains. Structure-Activity relationship data and ligand deconstruction highlight the importance of the substitution of the uracil moiety for potency and selectivity. Compound 3 was also cocrystallized with Brd4 for determining the ligand binding pose and rationalizing subsequent structure-Activity data. An additional series of dihydropyridopyrimidines was synthesized to exploit the proximity of a channel near the ZA loop of Brd4, leading to compounds with submicromolar affinity and cellular target engagement. Given these findings, novel and easily synthesized inhibitors are being introduced to the growing field of bromodomain inhibitor development.",
author = "Ayoub, {Alex M.} and Hawk, {Laura M.L.} and Herzig, {Ryan J.} and Jiewei Jiang and Wisniewski, {Andrea J.} and Gee, {Clifford T.} and Peiliang Zhao and Zhu, {Jin Yi} and Norbert Berndt and Offei-Addo, {Nana K.} and Scott, {Thomas G.} and Jun Qi and Bradner, {James E.} and Ward, {Timothy R.} and Ernst Sch{\"o}nbrunn and Georg, {Gunda I.} and Pomerantz, {William C.K.}",
year = "2017",
month = "6",
day = "22",
doi = "10.1021/acs.jmedchem.6b01336",
language = "English (US)",
volume = "60",
pages = "4805--4817",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen

AU - Ayoub, Alex M.

AU - Hawk, Laura M.L.

AU - Herzig, Ryan J.

AU - Jiang, Jiewei

AU - Wisniewski, Andrea J.

AU - Gee, Clifford T.

AU - Zhao, Peiliang

AU - Zhu, Jin Yi

AU - Berndt, Norbert

AU - Offei-Addo, Nana K.

AU - Scott, Thomas G.

AU - Qi, Jun

AU - Bradner, James E.

AU - Ward, Timothy R.

AU - Schönbrunn, Ernst

AU - Georg, Gunda I.

AU - Pomerantz, William C.K.

PY - 2017/6/22

Y1 - 2017/6/22

N2 - Chemical inhibition of epigenetic regulatory proteins BrdT and Brd4 is emerging as a promising therapeutic strategy in contraception, cancer, and heart disease. We report an easily synthesized dihydropyridopyrimidine pan-BET inhibitor scaffold, which was uncovered via a virtual screen followed by testing in a fluorescence anisotropy assay. Dihydropyridopyimidine 3 was subjected to further characterization and is highly selective for the BET family of bromodomains. Structure-Activity relationship data and ligand deconstruction highlight the importance of the substitution of the uracil moiety for potency and selectivity. Compound 3 was also cocrystallized with Brd4 for determining the ligand binding pose and rationalizing subsequent structure-Activity data. An additional series of dihydropyridopyrimidines was synthesized to exploit the proximity of a channel near the ZA loop of Brd4, leading to compounds with submicromolar affinity and cellular target engagement. Given these findings, novel and easily synthesized inhibitors are being introduced to the growing field of bromodomain inhibitor development.

AB - Chemical inhibition of epigenetic regulatory proteins BrdT and Brd4 is emerging as a promising therapeutic strategy in contraception, cancer, and heart disease. We report an easily synthesized dihydropyridopyrimidine pan-BET inhibitor scaffold, which was uncovered via a virtual screen followed by testing in a fluorescence anisotropy assay. Dihydropyridopyimidine 3 was subjected to further characterization and is highly selective for the BET family of bromodomains. Structure-Activity relationship data and ligand deconstruction highlight the importance of the substitution of the uracil moiety for potency and selectivity. Compound 3 was also cocrystallized with Brd4 for determining the ligand binding pose and rationalizing subsequent structure-Activity data. An additional series of dihydropyridopyrimidines was synthesized to exploit the proximity of a channel near the ZA loop of Brd4, leading to compounds with submicromolar affinity and cellular target engagement. Given these findings, novel and easily synthesized inhibitors are being introduced to the growing field of bromodomain inhibitor development.

UR - http://www.scopus.com/inward/record.url?scp=85021170306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021170306&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01336

DO - 10.1021/acs.jmedchem.6b01336

M3 - Article

C2 - 28535045

AN - SCOPUS:85021170306

VL - 60

SP - 4805

EP - 4817

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 12

ER -